IntelliStent is intended to achieve reduction of pulmonary hypertension, improvements in symptoms and quality of life in pediatric, adolescent and adult patients with congenital heart disease associated pulmonary arterial hypertension or left ventricular dilated cardiomyopathy.
IntelliStent Implant System is a kit of stents for adjustable interventional reduction of blood flow through a novel and minimally invasive intervention to replace surgical Pulmonary Artery Banding (PAB).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Staged implantation of IntelliStent. The system comprises a nitinol self-expanding stent with a hollow element delivered over-the-wire into the main pulmonary artery or its left and right branches, using an 18 Fr transfemoral introducer sheath. The stent consists of two sections, one with a larger diameter and one with a smaller diameter, available in 6 sizes suitable for vessel sizes ranging from 20mm to 30 mm. Additional smaller sizes are currently under development.
Change in pulmonary vascular resistance (PVR)
The primary efficacy endpoint is a binary variable. For patients with a baseline pulmonary vascular resistance (PVR) \>1000 dynes·s·cm-5, success is defined by an absolute reduction in PVR of ≥300 dynes·s·cm-5 at 24 weeks. For patients with a baseline PVR ≤1000 dynes·s·cm-5, success is a 30% reduction in PVR at 24 weeks.
Time frame: 24 Weeks
Six Minute Walk Test Distance
Change from baseline of six minute walk test distance (meters) at Week 12.
Time frame: 12 Weeks
Change From Baseline to Week 12 in Borg Dyspnea Score
The Borg Dyspnea score is a self-rating scale to evaluate the severity of dyspnea (from 0 "no shortness of breath at all" to 10 "very, very severe / maximal" shortness of breath).
Time frame: Baseline to 12 weeks
NYHA Class change from Baseline at Week 12
New York Heart Association Class (NYHA) class: minimum I; maximum IV ( worse)
Time frame: Baseline to 12 weeks
Change From Baseline to Week 12 in Ejection Fraction
Ejection Fraction (%) measured by transthoracic echocardiography
Time frame: Baseline to 12 Weeks
Change From Baseline to Week 12 in Left Ventricular Volumes
Left Ventricular Volumes measured by transthoracic echocardiography
Time frame: Baseline to 12 Weeks
Change From Baseline of the Kansas City Cardiomyopathy Questionnaire (KCCQ)
KCCQ scores for quality of life are scaled from 0 to 100 and summarized in 25-point ranges: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline to 12 Weeks